NKGN
NKGen Biotech Inc. · NASDAQ
- Sector Finance
- Industry Financial Conglomerates
- Website nkgenbiotech.com
- Employees(FY) -
- ISIN US65488A1016
Performance
-10.4%
1W
-7.44%
1M
-25.33%
3M
-61.11%
6M
-59.27%
YTD
-89.02%
1Y
Profile
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
Technical Analysis of NKGN 2024-05-10
Overview:
In analyzing the technical indicators for NKGN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Indicators:
- Moving Averages (MA): The 5-day MA has been consistently below the closing price, i...
Recent News & Updates
- 2024-05-15 20:05
- 2024-04-28 20:00
- 2024-04-25 04:05
- 2024-04-24 04:45
- 2024-04-18 04:05
- 2024-04-16 11:53
- 2024-04-10 20:05
- 2024-03-25 04:05
- 2024-03-05 18:52
Why Is NKGen Biotech (NKGN) Stock Up 62% Today?(Investorplace)
- 2024-03-03 19:00
- 2024-02-06 19:57
- 2023-12-28 18:30
- 2023-12-28 03:05
- 2023-12-26 19:00
- 2023-11-14 03:48
- 2023-10-25 20:00
- 2023-10-23 22:53
- 2023-10-23 20:00
- 2023-10-18 20:00
- 2023-10-16 20:00
- 2023-10-10 20:00
Page 1 of 1
previousnext